Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study

Research output: Contribution to journalArticle

348 Citations (Scopus)

Abstract

Background: Together with smoking, the lung function attained in early adulthood is one of the strongest predictors of chronic obstructive pulmonary disease. We aimed to investigate whether lung function in early adulthood is, in turn, affected by airway function measured shortly after birth. Methods: Non-selected infants were enrolled at birth in the Tucson Children's Respiratory Study between 1980 and 1984. We measured maximal expiratory flows at functional residual capacity (VmaxFRC) in 169 of these infants by the chest compression technique at a mean of 2·3 months (SD 1·9). We also obtained measurements of lung function for 123 of these participants at least once at ages 11, 16, and 22 years. Indices were forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and forced expiratory flow between 25% and 75% of FVC (FEF25-75), both before and after treatment with a bronchodilator (180 μg of albuterol). Findings: Participants who had infant VmaxFRC in the lowest quartile also had lower values for the FEV1/FVC ratio (-5·2%, p<0·0001), FEF25-75 (-663 mL/s, p<0·0001), and FEV1 (-233 mL, p=0·001) up to age 22, after adjustment for height, weight, age, and sex, than those in the upper three quartiles combined. The magnitude and significance of this effect did not change after additional adjustment for wheeze, smoking, atopy, or parental asthma. Interpretation: Poor airway function shortly after birth should be recognised as a risk factor for airflow obstruction in young adults. Prevention of chronic obstructive pulmonary disease might need to start in fetal life.

Original languageEnglish (US)
Pages (from-to)758-764
Number of pages7
JournalThe Lancet
Volume370
Issue number9589
DOIs
StatePublished - Sep 1 2007

Fingerprint

Vital Capacity
Forced Expiratory Volume
Longitudinal Studies
Cohort Studies
Parturition
Lung
Chronic Obstructive Pulmonary Disease
Smoking
Functional Residual Capacity
Albuterol
Bronchodilator Agents
Young Adult
Thorax
Asthma
Weights and Measures
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{0dbcb5c031f64c37838a4599824111f3,
title = "Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study",
abstract = "Background: Together with smoking, the lung function attained in early adulthood is one of the strongest predictors of chronic obstructive pulmonary disease. We aimed to investigate whether lung function in early adulthood is, in turn, affected by airway function measured shortly after birth. Methods: Non-selected infants were enrolled at birth in the Tucson Children's Respiratory Study between 1980 and 1984. We measured maximal expiratory flows at functional residual capacity (VmaxFRC) in 169 of these infants by the chest compression technique at a mean of 2·3 months (SD 1·9). We also obtained measurements of lung function for 123 of these participants at least once at ages 11, 16, and 22 years. Indices were forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and forced expiratory flow between 25{\%} and 75{\%} of FVC (FEF25-75), both before and after treatment with a bronchodilator (180 μg of albuterol). Findings: Participants who had infant VmaxFRC in the lowest quartile also had lower values for the FEV1/FVC ratio (-5·2{\%}, p<0·0001), FEF25-75 (-663 mL/s, p<0·0001), and FEV1 (-233 mL, p=0·001) up to age 22, after adjustment for height, weight, age, and sex, than those in the upper three quartiles combined. The magnitude and significance of this effect did not change after additional adjustment for wheeze, smoking, atopy, or parental asthma. Interpretation: Poor airway function shortly after birth should be recognised as a risk factor for airflow obstruction in young adults. Prevention of chronic obstructive pulmonary disease might need to start in fetal life.",
author = "Stern, {Debra A.} and Morgan, {Wayne J.} and Wright, {Anne L} and Stefano Guerra and Martinez, {Fernando D.}",
year = "2007",
month = "9",
day = "1",
doi = "10.1016/S0140-6736(07)61379-8",
language = "English (US)",
volume = "370",
pages = "758--764",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9589",

}

TY - JOUR

T1 - Poor airway function in early infancy and lung function by age 22 years

T2 - a non-selective longitudinal cohort study

AU - Stern, Debra A.

AU - Morgan, Wayne J.

AU - Wright, Anne L

AU - Guerra, Stefano

AU - Martinez, Fernando D.

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Background: Together with smoking, the lung function attained in early adulthood is one of the strongest predictors of chronic obstructive pulmonary disease. We aimed to investigate whether lung function in early adulthood is, in turn, affected by airway function measured shortly after birth. Methods: Non-selected infants were enrolled at birth in the Tucson Children's Respiratory Study between 1980 and 1984. We measured maximal expiratory flows at functional residual capacity (VmaxFRC) in 169 of these infants by the chest compression technique at a mean of 2·3 months (SD 1·9). We also obtained measurements of lung function for 123 of these participants at least once at ages 11, 16, and 22 years. Indices were forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and forced expiratory flow between 25% and 75% of FVC (FEF25-75), both before and after treatment with a bronchodilator (180 μg of albuterol). Findings: Participants who had infant VmaxFRC in the lowest quartile also had lower values for the FEV1/FVC ratio (-5·2%, p<0·0001), FEF25-75 (-663 mL/s, p<0·0001), and FEV1 (-233 mL, p=0·001) up to age 22, after adjustment for height, weight, age, and sex, than those in the upper three quartiles combined. The magnitude and significance of this effect did not change after additional adjustment for wheeze, smoking, atopy, or parental asthma. Interpretation: Poor airway function shortly after birth should be recognised as a risk factor for airflow obstruction in young adults. Prevention of chronic obstructive pulmonary disease might need to start in fetal life.

AB - Background: Together with smoking, the lung function attained in early adulthood is one of the strongest predictors of chronic obstructive pulmonary disease. We aimed to investigate whether lung function in early adulthood is, in turn, affected by airway function measured shortly after birth. Methods: Non-selected infants were enrolled at birth in the Tucson Children's Respiratory Study between 1980 and 1984. We measured maximal expiratory flows at functional residual capacity (VmaxFRC) in 169 of these infants by the chest compression technique at a mean of 2·3 months (SD 1·9). We also obtained measurements of lung function for 123 of these participants at least once at ages 11, 16, and 22 years. Indices were forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and forced expiratory flow between 25% and 75% of FVC (FEF25-75), both before and after treatment with a bronchodilator (180 μg of albuterol). Findings: Participants who had infant VmaxFRC in the lowest quartile also had lower values for the FEV1/FVC ratio (-5·2%, p<0·0001), FEF25-75 (-663 mL/s, p<0·0001), and FEV1 (-233 mL, p=0·001) up to age 22, after adjustment for height, weight, age, and sex, than those in the upper three quartiles combined. The magnitude and significance of this effect did not change after additional adjustment for wheeze, smoking, atopy, or parental asthma. Interpretation: Poor airway function shortly after birth should be recognised as a risk factor for airflow obstruction in young adults. Prevention of chronic obstructive pulmonary disease might need to start in fetal life.

UR - http://www.scopus.com/inward/record.url?scp=34548262715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548262715&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(07)61379-8

DO - 10.1016/S0140-6736(07)61379-8

M3 - Article

C2 - 17765525

AN - SCOPUS:34548262715

VL - 370

SP - 758

EP - 764

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9589

ER -